Evolution-guided discovery and recoding of allosteric pathway specificity determinants in psychoactive bioamine receptors

Verna and Marrs Mclean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
Proceedings of the National Academy of Sciences (Impact Factor: 9.67). 04/2010; 107(17):7787-92. DOI: 10.1073/pnas.0914877107
Source: PubMed


G protein-coupled receptors for dopamine and serotonin control signaling pathways targeted by many psychoactive drugs. A puzzle is how receptors with similar functions and nearly identical binding site structures, such as D2 dopamine receptors and 5-HT2A serotonin receptors, could evolve a mechanism that discriminates stringently in their cellular responses between endogenous neurotransmitters. We used the Difference Evolutionary Trace (Difference-ET) and residue-swapping to uncover two distinct sets of specificity-determining sequence positions. One at the ligand-binding pocket determines the relative affinities for these two ligands, and a distinct, surprising set of positions outside the binding site determines whether a bound ligand can trigger the conformational rearrangement leading to G protein activation. Thus one site specifies affinity while the other encodes a filter for efficacy. These findings demonstrate that allosteric pathways linking distant interactions via alternate conformational states enforce specificity independently of the ligand-binding site, such that either one may be rationally rekeyed to different ligands. The conversion of a dopamine receptor effectively into a serotonin receptor illustrates the plasticity of GPCR signaling during evolution, or in pathological states, and suggests new approaches to drug discovery, targeting both classes of sites.

Download full-text


Available from: Olivier Lichtarge, Feb 03, 2014
    • "Dopamine levels can be reduced using a partial D 2 agonist or an auto receptor agonist together with an antagonist for the central 5-HT 2A receptors [10]. Antipsychotic agents differ in their relative potency because of their ability to bind to multiple complex receptors of dopamine subtype receptors [11]. The signaling of the regulation and connections between the multiple copies of its cell surface receptors or that involve activity-dependent refinements of receptor binding sites across the signaling networks [12]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In this study, we have developed a novel molecular imprinting method for the cloning of a drug with multiple templates to achieve a broad selectivity, and then produce reactive dopamine analogs. The products were produced within selective recognition sites of the artificial system prepared against dopamine (D) and serotonin (S) as a single and a mixed template. As a consequence of the functionality of the anchoring sites being was able to make proximity changes that could promote changes in the nanosized space for surface access for the reactants but avoided the non-active center of the formed nanosized assembly. The most effective analogues had a Bmax of the DS-MIP (1.0 M per g polymer) that was about twice that of the D-MIP. The receptor-ligand interaction studies revealed differences in the absorbance by the rat hypothalamus, and indicated that an additional potent hit was obvious. The dopamine analogs had a smaller space for receptor subtypes as determined by molecular docking and the implication of the selective D3 receptor agonists as well as the 5HT1b receptors, for the treatment of Parkinson's disease. The proposed model indicated a possible role from the desired fragments that had been inserted into a specific binding pocket of the protein near to the gorge rim as being the significant pharmacophore of this class. They showed good binding affinity for the 5-HT1b receptors. The screening test with a natural D1 receptor yielded a Bmax of 0.44 μM and the corresponding Kd values were 100-500 nM. Thus, this process that occurred in an artificial dopamine-imprinted receptor allowed for preclinical testing to identify possible neuroleptic agents and their neuroprotective effects hopefully with reduced side effects.
  • Source
    • "In other words, the fitness metric and the action of a mutation are assumed to be time-invariant. This is an approximation since divergent proteins can develop new functional sites, a phenomena that leads to branch-specific evolutionary gradient variations and accounted for by differential ET (Lichtarge et al. 1997), for example, to identify ligand-specific sites (Madabushi et al. 2004; Rodriguez et al. 2010). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The relationship between genotype mutations and phenotype variations determines health in the short term and evolution over the long term, and it hinges on the action of mutations on fitness. A fundamental difficulty in determining this action, however, is that it depends on the unique context of each mutation, which is complex and often cryptic. As a result, the effect of most genome variations on molecular function and overall fitness remains unknown, and stands apart from population genetics theories linking fitness effect to polymorphism frequency. Here, we hypothesize that evolution is a continuous and differentiable physical process coupling genotype to phenotype. This leads to a formal equation for the action of coding mutations on fitness that can be interpreted as a product of the evolutionary importance of the mutated site with the difference in amino acid similarity. Approximations for these terms are readily computable from phylogenetic sequence analysis, and we show mutational, clinical, and population genetic evidence that this action equation predicts the effect of point mutations in vivo and in vitro in diverse proteins, correlates disease-causing gene mutations with morbidity, and determines the frequency of human coding polymorphisms, respectively. Thus elementary calculus and phylogenetics can be integrated into a perturbation analysis of the evolutionary relationship between genotype and phenotype that quantitatively links point mutations to function and fitness and that opens a new analytic framework for equations of biology. In practice, this work explicitly bridges molecular evolution with population genetics with applications from protein redesign to the clinical assessment of human genetic variations.
    Genome Research 09/2014; 24(12). DOI:10.1101/gr.176214.114 · 14.63 Impact Factor
  • Source
    • "By swapping residues, we rewired the transcriptional specificity of the bHLH proneural transcription factors from the frog homologue to the fly homologue, and vice-versa (Quan et al., 2004). In a more recent application, we demonstrated the ability to rewire the allosteric pathway in the Dopamine receptor, D2, to increase response to serotonin (Rodriguez et al., 2010). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Understanding the molecular basis of protein function remains a central goal of biology, with the hope to elucidate the role of human genes in health and in disease, and to rationally design therapies through targeted molecular perturbations. We review here some of the computational techniques and resources available for characterizing a critical aspect of protein function - those mediated by protein-protein interactions (PPI). We describe several applications and recent successes of the Evolutionary Trace (ET) in identifying molecular events and shapes that underlie protein function and specificity in both eukaryotes and prokaryotes. ET is a part of analytical approaches based on the successes and failures of evolution that enable the rational control of PPI.
    Progress in Biophysics and Molecular Biology 05/2014; 116(2-3). DOI:10.1016/j.pbiomolbio.2014.05.004 · 2.27 Impact Factor
Show more